Compare Sanofi SA (SNY) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Sanofi SA trades at $42.7 (market cap $104.06B), while Direxion Daily S&P 500 Bull 3X Shares trades at $283.6. The key difference: Sanofi SA pays a 5.61% dividend while Direxion Daily S&P 500 Bull 3X Shares pays none, and Direxion Daily S&P 500 Bull 3X Shares is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | SPXL | |
|---|---|---|
Market Cap | $104.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $52.34 | $301.38 |
52-Week Low | $41.33 | $170.20 |
Enterprise Value | $124.09B | — |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
SPXL, a leveraged ETF tracking the S&P 500, trades at $285.5, down 1.67% amid broader market caution. Technical indicators show a neutral overall signal with bullish moving averages, while support sits at $284 and resistance at $289. Recent news highlights market resilience despite geopolitical tensions and high valuations, with the S&P 500 up 13% over six months amid Iran conflicts.
The outlook remains mixed: AI-driven earnings growth supports further gains, but elevated valuations and Fed rate risks pose headwinds. Investors face volatility from oil prices and trade policies, yet long-term index fund strategies are favored by analysts targeting S&P 500 levels near 8,000.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
